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Ezzeldin M Ibrahim1*†, Khaled M Abouelkhair1, Ghieth A Kazkaz1, Osama A Elmasri1 and Meteb Al-Foheidi2†Abstract
Background: Women treated for Hodgkin’s lymphoma (HL) have an elevated risk of developing second breast
cancer (SBC) compared with the general population. We planned this meta-analysis to quantify the long-term risk
of SBC and analyze the contributing risk factors among HL survivors.
Methods: According to predefined selection criteria, literature search identified 34 studies that were included in the
analyses.
Results: After eliminating overlapping or duplicate data, 957 incidences of SBC were encountered in 24,505 females
with HL over a median follow-up of 14.9 years. The medians: age at the diagnosis of HL, age at diagnosis of SBC,
and latency since HL treatment to the development of SBC were 23.7, 35.0, and 17.7 years, respectively. The pooled
relative risk (RR) of SBC was 8.23 (95% CI, 5.43-12.47, I2= 96%), with a median absolute excess rate of 22.9 per 10,000
person-years. The RR was found inversely related to age at diagnosis of HL with the highest rate (68.7; [95%CI,
28.08-168.11], I2= 79%), occurred in young patients (≤ 15 years old), where the RR in older women (≥ 40 years old)
was not significant (0.55; [95% CI, 0.09-3.52]). Analysis of RR by 5-year increments since the treatment of HL showed
that the risk was highest after 15–19 years of latency (13.87; [95% CI, 7.91-24.30], I2= 89%). Analysis of the effect of
treatment modalities showed that the RR rates were (4.70; [95% CI, 3.28-6.75], I2= 74%), (5.65; [95%CI, 2.94-10.88],
I2= 91%), and (1.19; [95% CI, 0.50-2.82], I2= 65%), for radiotherapy (RT) only, combined RT and chemotherapy (CT),
and CT only, respectively. To investigate the demonstrated heterogeneity, meta-regression analysis was performed
when feasible. In most such analyses, the natural logarithm of RR was inversely associated with age at HL diagnosis.
Conclusions: We conclude that, the current meta-analysis provided the most recent comprehensive estimate of
the risk of SBC in a broad-range of HL survivors. Younger age at diagnosis proved to be a dominant risk factor. The
obtained results would serve providing breast cancer screening recommendations for HL survivors.Background
Hodgkin’s lymphoma (HL) became a curable disease by
radiation therapy (RT) and/or combination chemother-
apy (CT) since the early 70s [1-3]. Long-term disease-
free survival of 70% to 90%, depending on stage at
diagnosis has been achieved [4], and even more favor-
able outcome has been demonstrated in pediatrics, with
a 5-year survival exceeding 90% [5].
However, increased risk of second cancer following ef-
fective treatment of HL has long been reported [6].
More recently, second neoplasms after HL are being* Correspondence: ezzibrahim@imc.med.sa
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reproduction in any medium, provided the orencountered with increasing frequency due to the
marked improvement in survival [2,7]. The particular
elevated risk of second breast cancer (SBC) among this
population is not surprising in view of the reported ex-
cess risks of breast cancer (BC) after incidental low
doses of ionizing radiation [8,9], therapeutic RT [10,11],
or as sequelae of the carcinogenic effects of CT [12,13].
Two pertinent meta-analyses have been published and
they have addressed different questions. The first meta-
analysis was published in 2006 and examined all second
malignancy risk associated with HL treatment in 31 ran-
domized trials and it included 65 incidence of SBC [14].
In the second meta-analysis [15], SBC risk and BC sur-
veillance were investigated in young females (≤ 30 years
at the primary tumor diagnosis) receiving moderate to
high doses of RT targeted to mantle and modifiedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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latter meta-analysis comprised 11 studies that were not
restricted to patients with HL but included all primary
neoplasms in that age group.
Research on the late consequences of HL has often
been limited by the size and composition of the study
populations and by the duration and completeness of
patient follow-up. To the best of our knowledge, there is
no recently published meta-analysis intended to examine
the risk of SBC in a broad range of ages at HL diagnosis,
various follow-up periods, and subsequent to different
therapeutic modalities. Also not precisely known, is the
effect of other contributing risk factors. The lack of such
data has prompted the current meta-analysis.
Methods
Search strategy
Between January 1966 and October 2011, we identified
studies of interest by first conducting an electronic lit-
erature search of the databases MEDLINE, EMBASE,
and the Cochrane Library. We also searched for relevant
abstracts in the annual conference proceedings between
January 1984 to October 2011 for the American Society
of Clinical Oncology, European Society for Medical On-
cology, and the San Antonio Breast Cancer Symposium.
All ages of HL patients were eligible for inclusion.
We used exploded Medical Subject Heading terms or
key words terms ‘lymphoma’, ‘Hodgkin’, ‘Hodgkin’s dis-
ease’ and ‘Hodgkin’s lymphoma’. The terms were com-
bined with ‘neoplasm, second neoplasm, second primary’
using the Boolean operator ‘and’. Search results were
also filtered against the terms ‘breast, breast cancer,
breast neoplasm). In the second step, these keywords
were combined using the Boolean operator ‘and’ with
‘standardized incidence ratio’, ‘relative risk’, and ‘observed
to expected’. In addition, we manually reviewed the
reference lists of relevant studies to identify additional
pertinent published articles.
Selection criteria
We included studies that met each of following criteria:
(i) published in English language between January 1985
and October 2011; (ii) included naive patients at any age
and with any stage of HL; (iii) investigated the risk for
second malignant neoplasms (SMNs) in HL survivors;
(iv) reported relative risk (RR) and/or specified as stan-
dardized incidence ratios (SIR) or data allowing such
outcomes to be derived; and (v) published as original
articles (no case reports, case series, reviews, comments,
letters, or editorials).
When two or more references reported duplicate data,
we only included in the analysis the most recent data,
studies with the longer follow-up, or the most relevant
studies. We excluded studies that mainly addressed theclinical characteristics of SBC. We also excluded studies
that mainly intended to evaluate the potential benefits
and harms associated with breast cancer surveillance
among women with HL. Case–control designs, i.e. HL
patients who developed BC compared with patients who
did not were excluded.
Data extraction
Two authors (KMA, and GAK) independently inspected
each reference title identified by the search and applied
the inclusion criteria. For possibly relevant articles and
in cases of disagreement between reviewers, the full art-
icle was obtained and inspected independently by the
five authors. The data intended for extraction were dis-
cussed, and decisions were documented. We used the
STROBE (Strengthening the Reporting of Observational
Studies in Epidemiology) reporting criteria to assess the
quality of studies included in the meta-analysis [16]. Any
significant lack of concordance in the scores assigned by
authors was discussed to reach a consensus.
Standardized Excel sheet was used for each study that
fulfilled the inclusion criteria. Extracted data included
paper characteristics (first author’s last name, publica-
tion year, country in which the study was carried out,
and data source), study design, number of HL patients,
mean/median age of patients, mean/median duration of
follow-up, therapy details, number of observed and
expected SBC cases, and RR or standardized-incidence
rate (SIR) with corresponding 95% confidence interval
(CI). The ratio of observed to expected numbers of can-
cers, SIR (referred to in the text as RR) was then used or
calculated with likelihood-based 95% CI from Poisson
models [17]. Where not reported, we computed the CI
for the risk assuming a Poisson distribution for the
observed number of cases. Standard error (SE) for the
natural logarithm of RR (lnRR) was derived from CI, ap-
plying the following equation: SE = ln(upper 95% CI/
lower 95% CI)/(2 x z1 - a/2). When appropriate, we also
used the built-in calculator of the Review Manager Soft-
ware (version 5.1.4 for Windows; The Cochrane Collab-
oration, Oxford, UK) to compute missing data. When
studies showed that the observed number of cases was
zero, we simply added 1 to both the observed and the
expected number of cases to allow computation of an
estimate of the lnRR and its associated SE [18].
Outcome measures
The primary outcome was the overall pooled RR of inci-
dence of SBC among women survivors of HD. The sec-
ondary end points were RR vs. various variables: source of
data, age at diagnosis of HD, length of follow-up, treat-
ment modalities, and any additional relevant risk factors.
RT in this meta-analysis is referred to supra-diaphrag-
matic irradiation with or without other radiation fields.
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We assessed heterogeneity of the studies’ results by
inspecting graphical presentations and by calculating an
x2 test of heterogeneity and the I2 statistic of inconsist-
ency [19,20]. Statistically significant heterogeneity was
defined as a x2 P value less than .1 or an I2 statistic
greater than 50%. The estimates of RR, together with
associated 95% CI, were obtained using the DerSimonian
and Laird random-effects model [21]. Meta-regression
analysis was performed to determine to what extent the
heterogeneity is explained by various covariates using
IBM SPSS statistical package v.19. The dependent vari-
able was the lnRR weighted for the inverse of variance
to perform weighted least square linear regression. We
first conducted a univariate regression analysis for each
variable followed by a multivariate regression including
variables found significant in the univariate analysis.
Subgroup analyses were performed to assess potential
contributions of various clinical variables to outcomes.
A funnel plot estimating the precision of trials (plots of
logarithm of the RR against the sample size) was exam-
ined for asymmetry to estimate publication bias [22].
Publication bias was also quantified by the regression
asymmetry test by Egger [22].
All statistical tests were two-sided. RR was estimated
according to the inverse of variance method with the
use of Review Manager Software v5.1.4.
Results
Search results
We identified 1,647 potentially relevant articles (Figure 1).
After exclusion of duplicate references, none-relevant lit-
erature, and those that did not satisfy inclusion criteria,
41 candidate articles were considered for the meta-ana-
lysis [23-62]. After careful review of the full text of these
articles, 7 studies were excluded. In 5 studies the RR was
reported based on case–control design, i.e. HL patients
who developed SBC against patients who did not
[33,43,47,63,64]. The RR in the sixth excluded study
compared RR among HL patients according to presence
or absence of a family history of BC [50]. The seventh
excluded study was designed to examine RT dose and
dose distribution in 41 HL patients (25 females) treated
at a single Canadian institution [49].
The remaining 34 studies were included in the meta-
analysis. The funnel plot of 25 non-overlapping studies
showed mild asymmetry, however, the Egger linear re-
gression test was not significant (P= .059).
Of the 34 included studies, there were several reports of
overlapping and/or updated data with longer follow-up and
more encountered events. For any analysis, only the
updated results were used unless there were relevant data
available in earlier report and were not included in more re-
cent publication. That approach was used to deal with theoverlapping data of van Leeuwen et al. [25] (2 Dutch
institutes) and De Bruin et al. [55] (5 Dutch institutes);
Mauch et al. [26] (5 USA institutes) and Ng et al. [41] (4
USA institutes); Aisenberg et al. [28] and Alm El-Din
et al. [54] (single USA institute); Basu et al. [52] and
Constine et al. [53] (5 USA institutes); Neglia et al. [39],
Kenney et al. [45], and Castellino et al. [59] (the multi-
institutional USA Childhood Cancer Survivor Study);
Metayer et al. [35] (16 population-based cancer registries
in North America and Europe, Hodgson et al. [48] (13
population-based cancer registries in North America and
Europe), and that of Dores et al. [57] (9 population-
based cancer registries in the USA); Hancock et al. [24],
Wolden et al. (1998) [30], O'Brien [58], and Wolden
et al. (2000) [37] (single USA institute); and Swerdlow
et al. [36], and Swerdlow et al. [62] for the British Na-
tional Lymphoma Investigation.
Tables 1 and 2 show the abstracted and computed data
of the included studies. Overlapping studies were shaded
together. The data sets included patients diagnosed as
early as 1935 to the late 2000s. The median duration of
follow-up since the diagnosis of HL was 14.9 years (95%
CI, 13.0-16.2 years; ranging from 6 to 23.8 years), while
the median age at the diagnosis of HL was 23.7 years
(95% CI, 18.9-25.5 years; ranging from 11.8 to 40 years),
and the median age at the diagnosis of SBC was
35.0 years (95% CI, 30.2-40.0 years; ranging from 12.8 to
44.4 years). The median interval between primary diag-
nosis and development of SBC was 17.7 years (95% CI,
15.2-18.6 years; ranging from 12.2 to 21.6 years).
After eliminating overlapping and duplicate studies,
there were 25,305 women with HL and 957 inci-
dences of SBC. The median absolute excess rate
(AER) of SBC incidence per 10,000 person-years of
observation was 22.9 excess cases (95%CI, 15.6-55.7,
ranging from 1.1 to 174). Few studies reported the
cumulative incidence of SBC after 20 and 30 years of
follow-up (average: 5.4% and 12%, respectively).
Pooled RR
Figure 2 depicts the Forest plot for the pooled RR. The
fixed-effects model showed significant heterogeneity
(I2 statistic = 96%; p <0.0001). The random-effects model
was computed instead and it showed that patients with
HL have an almost 9-fold increase in the risk of SBC
(RR=8.23; [95% CI, 5.43-12.47], I2= 96%). We performed
meta-regression analysis to determine to what extent the
heterogeneity is explained by the effects of study size, age
at HL diagnosis, and the latency since the completion of
HL treatment. The univariate analysis showed significant
inverse association between lnRR and age at diagnosis and
a positive relation to latency since HL treatment. With
multivariate analysis (Table 3), only younger age at diag-
nosis remained significant (<0.0001).
Figure 1 Search results and the selection of 33 included studies.
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higher risk in institutional studies (RR=8.86; [95% CI,
5.26-14.94] compared with population-based analyses
(6.70; [95% CI, 4.07-11.03]). The demonstrated heterogen-
eity (I2=96%) was explored by meta-regression analysis,
however, none of variables tested was found associated
with lnRR in the univariate analysis (data not shown).
RR and age at diagnosis of HL
The excess risk of SBC as a function of age at diagnosis of
HL was also explored. Figure 4 (random-effects model)
shows that the RR of developing SBC decreased signifi-
cantly with increasing age at diagnosis from 68.7 (95% CI,
28.8-168.11, ≤ 15 years old) to 22.32 (95% CI, 13.4-37.16,
15–19 years old), 14.43 (95% CI, 11.65-17.88, 20–24 years
old), and 6.6 (95% CI, 4.24-10.29, 25–29 years old). As asignificant heterogeneity was shown (I2=79%), we per-
formed a meta-regression analysis, however, none of the ex-
planatory variables was found significant (data not shown).
Several studies reported the RR at certain cut points of
age at diagnosis and it also showed an inverse relation
between risk and age (Figure 5, fixed-effects model). In
the latter analysis and contrary to analysis of RR against
more age intervals, no significant heterogeneity was
noted (I2= 41%). Of note, the RR of SBC for women
who developed HL above the age of 40 years was not
significant (RR= 0.55; [95% CI, 0.09-3.52]).
RR and follow-up latency
We performed analysis of RR by 5-year increments since
the treatment of HL (Figure 6, random-effects model,
I2= 73%). By and large, the analysis demonstrated an
Table 1 Country, study period, design, source of data, study quality, and Hodgkin’s lymphoma therapy details of the 34 studies included in the meta-analysis










Coleman 1987 [23] UK 1961-1980 PBCS. Cancer registry 25/32 (35–36) (20–28) (27–34) Therapy data for M+ F
HL patients. Number NR.




24/31 383 (43) 30 (3) 341 (39) Therapy data for M+ F HL patients.
15% did not receive any treatment.
Wolden 1998 [30] USA 1960-1995 Single institution cohort
study (HL Dx. ≤21y)
Computerized database
and patient records
22/31 144 (47) 9 (3) 154 (50) Therapy data for female patients




24/32 37 (57) 1 (2) 27 (41) Therapy data for SBC
patients. 27 patients
received alkylating CTX.




23/31 0 (0) 0 (0) 35 (100) Therapy data for M+ F
pediatric HL patients.








22/30 552 (29) 178 (9) 1209 (62) Therapy data for M+ F
HL patients. All SBC received RT.




25/32 357 (31.8) 80 (7.1) 685 (61.1) Therapy data for all
HL female patients
Mauch 1996 [26] USA 1969-1988 5 institutions
cohort study
Institutional records 25/31 489 (62) 0 (0) 305 (38) Therapy data for M+ F
HL patients
Ng 2002 [41] USA 1969–1997 4 institutions cohort study Institutional records 26/32 665 (69) 0 (0) 296 (31) Therapy data for M+ F HL patients
Sankila 1996 [27] Nordic countries 1940-1987 5 Nordic PBCS
(HL Dx. ≤20y)
National cancer registries 21/31 NR NR NR All SBC patients received RT
Metayer 2000 [36] USA and Europe 1935–1994 16 PBCS (HL Dx. ≤21y,
1-year survivors)
National cancer registries 22/32 NR NR NR






First raw: therapy data for M+ F
HL patients. (27% with unknown
treatment). Second raw:therapy
data for SBC patients (28% with
unknown treatment)




22/32 NR NR NR All patients had RT
Aisenberg 1997 [28] USA 1964-1984 Single institution
cohort study
Review of patient records 21/31 10 (71) 0 (0) 4 (29) Therapy data for SBC patients
(4 patients had alkylating CTX)
Alm El-Din 2009 [54] USA 1964-2001 Single institution
cohort study






First raw: therapy data for all
patients (26% had alkylating CTX)
Second raw: therapy data for SBC
(22% had alkylating CTX)
Hudson 1998 [29] USA 1968-1990 Single institution Review of patient records 21/30 116 (30) 15 (4) 256 (66) Therapy data of M+ F HL patients
Gervais-Fagnou
1999 [31]
Canada 1965-1990 Single institution cohort
study (HL Dx. at ≤30y)
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patient & family contact
24/31 484 (43.1) 169 (15.1) 464 (41.4) Therapy data of M+ F HL patients
(8/9 SBC patients received RT)
Green 2000 [34] USA 1960-1989 Single institution cohort
study (HL ≤20y at Dx.)
Patient records and
mail contact
24/30 1 (25) 0 (0) 3 (75) Therapy data for SBC patients
Swerdlow 2000 [36] United Kingdom 1963-1993 BNLI (cohort study) BNLI + 2 cancer databases 24/31 1449 (27) 1693 (31) 2327 (42) Therapy data of M+ F HL patients
(all SBC had RT)
Swerdlow 2011 [62] United Kingdom 1963-2001 BNLI (cohort study) BNLI database
(70 institutions)
25/31 0 (0) 2366 (41) 3432 (59) Therapy data of M+ F HL patients
(SBC: 14% CTX only, 86% CTX+ RT)
Cellai 2001 [38] Italy 1960-1991 Single institution
cohort study
Institutional patient records 22/30 546 (36) 325 (21) 653 (43) Therapy data of M+ F HL patients
(SBC patients: 6% RT, 94% RT+CTX)
Neglia 2001 [39] USA and Canada 1970-1986 25 institutions (CCSS)
cohort study
(≤21y at HL Dx.,
5-y survivors)
Institutional patient records 26/32 NR NR NR Therapy data were reported for all
children malignancies combined
Kenney 2004 [45] USA and Canada 1970-1986 Same as Neglia et al. [40] Institutional patient records 26/32 NR NR NR Therapy data were reported for all
children malignancies combined
Castellino 2011 [59] USA and Canada 1970-1986 Same as Neglia et al. [40]
and Kenny et al. [46]




Norway 1968-1985 Single institution cohort
study (HD≥ 1y survivors)
National cancer registry 21/30 447 (44) 202 (20) 363 (36) Therapy data of M+ F HL patients
Bhatia 2003 [42] USA and Europe 1955-1986 15 institutions
cohort study






First raw: therapy data of M+ F
HL patients Second raw: therapy
data of SBC patients
Wahner-Roedler
2003 [44]
USA 1950-1993 Single institution
cohort study






First raw: therapy data of M+ F
HL patients Second raw: therapy
data of SBC patients
Behringer 2004 [60] Germany 1981-1989 Multi-Institutional
cohort study
German HL database 23/31 675 (12.9) 618 (11.8) 3947 (75.3) Therapy data of M+ F HL patients
Guibout 2005 [46] UK and France 1954-1985 8 institutions cohort study Institutional patient records 28/32 28 (23) 9 (7) 86 (70) Therapy data of M+ F HL patients








First raw: therapy data of female
HL patients Second raw: therapy
data of SBC patients
Basu 2008 [52]
Constine 2008 [53]
USA 1960-1990 5 institutions cohort
study (<19y at HL Dx.)






First raw: therapy data of M+ F
HL patients Second raw: therapy
data of SBC patients
Howell 2009 [56] UK 1965-2008 Cohort from a registry
and single institution
Institutional patient
records and a registry data
27/31 6 (26) 0 (0) 17 (74) Therapy data of SBC patients
Inskip 2007 [61] USA 1973-2002 PBCS (< 18y at Dx) SEER database 29/31 NR NR NR
BNLI British National Lymphoma Investigation, CCSS Childhood Cancer Survivors Study, Dx. diagnosis, HL Hodgkin’s lymphoma, M+F males and females, NR not reported or data could not be calculated, PBCS
population-based cohort study, RT radiotherapy that included supra-diaphragmatic irradiation, SBC second breast cancer, SEER Surveillance Epidemiology and End Results, STROBE Strengthening the Reporting of
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Coleman 1987 [23] UK 1961-1980 PBCS. Cancer registry 25/32 (35–36) (20–28) (27–34) Therapy data for M+ F
HL patients. Number NR.




24/31 383 (43) 30 (3) 341 (39) Therapy data for M+ F
HL patients. 15% did not
receive any treatment.





22/31 144 (47) 9 (3) 154 (50) Therapy data for
female patients




24/32 37 (57) 1 (2) 27 (41) Therapy data for SBC patients.
27 patients received
alkylating CTX.




23/31 0 (0) 0 (0) 35 (100) Therapy data for M+ F
pediatric HL patients.
All received low-dose
RT and alkylating CTX.
van Leeuwen
1994 [25]




22/30 552 (29) 178 (9) 1209 (62) Therapy data for M+ F
HL patients.
All SBC received RT.





25/32 357 (31.8) 80 (7.1) 685 (61.1) Therapy data for all
HL female patients
Mauch 1996 [26] USA 1969-1988 5 institutions
cohort study
Institutional records 25/31 489 (62) 0 (0) 305 (38) Therapy data for M+ F
HL patients
Ng 2002 [41] USA 1969–1997 4 institutions
cohort study
Institutional records 26/32 665 (69) 0 (0) 296 (31) Therapy data for M+ F
HL patients
Sankila 1996 [27] Nordic countries 1940-1987 5 Nordic PBCS
(HL Dx. ≤20y)
National cancer registries 21/31 NR NR NR All SBC patients received RT
Metayer 2000 [36] USA and Europe 1935–1994 16 PBCS (HL Dx.
≤21y, 1-year
survivors)
National cancer registries 22/32 NR NR NR
Hodgson 2007 [48] USA and Europe 1970-2001 13 PBCS
(5-year survivors)






First raw: therapy data for




SBC patients (28% with
unknown treatment)




22/32 NR NR NR All patients had RT
Aisenberg 1997 [28] USA 1964-1984 Single institution
cohort study
Review of patient records 21/31 10 (71) 0 (0) 4 (29) Therapy data for SBC patients
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Alm El-Din 2009 [54] USA 1964-2001 Single institution
cohort study






First raw: therapy data for all
patients (26% had alkylating
CTX) Second raw:
therapy data for SBC (22%
had alkylating CTX)




Canada 1965-1990 Single institution
cohort study
(HL Dx. at ≤30y)
Review of patient records 22/30 225 (55) 0 (0) 186 (45) Therapy data of M+ F
HL patients
Munker 1999 [32] Germany 1974-1994 6 institutions
cohort study
Munich tumor registry, patient
records, and patient
& family contact
24/31 484 (43.1) 169 (15.1) 464 (41.4) Therapy data of
M+ F HL patients
(8/9 SBC patients received RT)
Green 2000 [34] USA 1960-1989 Single institution
cohort study
(HL ≤20y at Dx.)
Patient records and
mail contact
24/30 1 (25) 0 (0) 3 (75) Therapy data for SBC patients
Swerdlow 2000 [36] United Kingdom 1963-1993 BNLI (cohort study) BNLI + 2 cancer databases 24/31 1449 (27) 1693 (31) 2327 (42) Therapy data of M+ F
HL patients
(all SBC had RT)
Swerdlow 2011 [62] United Kingdom 1963-2001 BNLI (cohort study) BNLI database (70 institutions) 25/31 0 (0) 2366 (41) 3432 (59) Therapy data of M+ F
HL patients
(SBC: 14% CTX only,
86% CTX+ RT)
Cellai 2001 [38] Italy 1960-1991 Single institution
cohort study
Institutional patient records 22/30 546 (36) 325 (21) 653 (43) Therapy data of M+ F
HL patients
(SBC patients: 6% RT,
94% RT+CTX)





Institutional patient records 26/32 NR NR NR Therapy data were reported
for all children
malignancies combined
Kenney 2004 [45] USA and Canada 1970-1986 Same as Neglia
et al. [40]
Institutional patient records 26/32 NR NR NR Therapy data were reported
for all children
malignancies combined
Castellino 2011 [59] USA and Canada 1970-1986 Same as Neglia
et al. [40] and
Kenny et al. [46]




Norway 1968-1985 Single institution
cohort study
(HD≥ 1y survivors)
National cancer registry 21/30 447 (44) 202 (20) 363 (36) Therapy data of M+ F
HL patients
Bhatia 2003 [42] USA and Europe 1955-1986 15 institutions
cohort study






First raw: therapy data
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Second raw: therapy
data of SBC patients
Wahner-Roedler
2003 [44]
USA 1950-1993 Single institution
cohort study






First raw: therapy data
of M+ F HL patients
Second raw: therapy data
of SBC patients
Behringer 2004 [60] Germany 1981-1989 Multi-Institutional
cohort study
German HL database 23/31 675 (12.9) 618 (11.8) 3947 (75.3) Therapy data of M+ F
HL patients
Guibout 2005 [46] UK and France 1954-1985 8 institutions
cohort study
Institutional patient records 28/32 28 (23) 9 (7) 86 (70) Therapy data of M+ F
HL patients








First raw: therapy data of
female HL patients




USA 1960-1990 5 institutions
cohort study
(<19y at HL Dx.)






First raw: therapy data
of M+ F HL patients
Second raw: therapy data of
SBC patients




records and a registry data
27/31 6 (26) 0 (0) 17 (74) Therapy data of SBC patients
Inskip 2007 [61] USA 1973-2002 PBCS (< 18y at Dx) SEER database 29/31 NR NR NR
*Absolute excess rate of SBC incidence cases per 10,000 person-years of follow-up.
CI confidence interval, Cum. Cumulative, DCIS ductal carcinoma in-situ, HL Hodgkin’s lymphoma, MF males and females, NR not reported or data could not be calculated, O/E observed/expected, RR relative risk, SBC

















Figure 2 Summary statistics and corresponding forest plot for the overall relative risk (RR) of second breast cancer as reported from
23 studies. RRs were calculated using a random-effects model.
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reaching the highest after 15–19 years (RR = 13.87; [95%
CI, 7.91-24.30]). While there was a decrease in RR noted
after 20–24 years of follow-up, further rise occurred
after 25–29 years. The latter rise may be attributed to
the RR reported by De Bruin et al. [55], while all the
other studies demonstrated a decreased RR after 25–
29 years compared with that after 20–24 years of follow-
up. Due to unreported data, meta-regression analysis of
the heterogeneity could only include age at diagnosis of
HL as the sole explanatory variable and it showed an in-
verse association with lnRR (Table 3).
After ≥ 20 years of latency since diagnosis, 9 studies
[37,40,41,44,45,48,51,54,55] reported RR of 6.95 (95% CI,Table 3 The results of meta-regression analyses
Model Covariates Meta-regre
Pooled RR for included
studies (Figure 2)
Age at HL diagnosis
Latency since HL treatment
RR versus follow-up
intervals (Figure 6)
Age at HL diagnosis
RR versus therapy modality
(Figure 7): RT vs. RT + C vs. C
Age at HL diagnosis
Latency since HL treatment
C chemotherapy, CI confidence interval, HL Hodgkin’s lymphoma, RR relative risk, RT4.8- 10.1). That RR was not significantly different
from the rate encountered after ≥ 30 years of follow-
up (RR = 7.03; [95% CI, 5.2-9.5]) as reported from 5
studies [42,44,51,54,55].
RR vs. Age at HL diagnosis and follow-up latency
To examine the interaction of both age at HL diagno-
sis and length of follow-up versus risk, few studies
have reported adequate data. De Bruin et al. [55]
reported that after 5–14 years of follow-up, those who
were ≤ 20 years at HL diagnosis had significantly higher
risk (RR= 20.0; [95% CI, 7.3-43.4]) as compared with
those who were older (21–30 years old) (RR = 5.3; [95%












radiotherapy, SE standard error.
Figure 3 Summary statistics and corresponding forest plot for the relative risk (RR) of second breast cancer in institutional vs.
population-based studies. RRs were calculated using a random- effects model.
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were 14.2 (95% CI, 7.9-25.4), and 9.0 (95% CI, 4.9-
16.5), respectively.
RR and treatment modalities
Figure 7 shows the random-effects model for the RR
according to HL treatment modalities. Significant het-
erogeneity was demonstrated (I2= 87%). RT used as the
sole therapeutic modality was associated with an almost
5-fold increase in risk (RR= 4.70; [95% CI, 3.28-6.75]),
I2= 74%) and even higher rate (RR= 14.08; [95% CI,
9.93-19.98]) when RT was used for patients≤ 30 years of
age [32,36,41]. Two studies [24,54], reported on the
mantle field RT dose where there was a small difference
in RR between dose< 40 Gy and ≥ 40 Gy (5.99, and 6.13,respectively). In the first study [24], 1 patient per 567
person-years risk versus 23 patients per 7876 person-
years developed SBC in the lower versus higher RT dose,
respectively. In the second study, 17 of 135 versus 18 of
109 patients developed SBC in the lower versus higher
RT dose, respectively [54]. When reported, almost all
SBC arose within or at the margin of RT field.
Figure 7 also shows that adding any CT to RT numer-
ically increased the risk as compared with the risk asso-
ciated with RT only (RR= 5.65; [95%CI, 2.94-10.88],
I2= 91%). Nevertheless, adding alkylating CT to RT did
not abate SBC risk (RR= 6.59; [95% CI, 1.72-25.20),
while the combination of RT and non-alkylating CT
caused a non-significant effect (RR = 4.40; [95% CI, 0.83-
23.38]) (data not shown). Noteworthy, only a few studies
Figure 4 Summary statistics and corresponding forest plot for the relative risk (RR) of second breast cancer based on the age at
Hodgkin’s lymphoma diagnosis. RRs were calculated using a random-effects model.
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offered. The current meta-analysis showed that the use
of CT only was not associated with significant risk
(RR = 1.19; [95% CI, 0.50-2.82], I2= 87%).
To explore the heterogeneity of the RR vs. therapeutic
modalities, we performed a univariate analysis that showed
an inverse association between lnRR and age at HL diag-
nosis, positive interaction with latency, and no significant
effect for study size. The multivariate meta-regressionanalysis, however, only showed that younger age at diagno-
sis retained a significant independent risk (Table 3).RR and additional contributing factors
Comparing HL patients diagnosed from 1960s to the
early 1970s, late 1970s to early 1980s, and more recent
years the reported RRs were 3.7, 5.9, and 10.7, respect-
ively [23,28,48,51,55].
Figure 5 Summary statistics and corresponding forest plot for the relative risk (RR) of second breast cancer based on specific cut
points of age at Hodgkin’s lymphoma diagnosis. RRs were calculated using a fixed-effects model.
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factors. Pooled analysis was not attempted due to the
small number of studies with sufficient data. Table 4
shows that HL patients who presented with mediastinal
mass had higher risk compared with those without me-
diastinal mass. Table 4 also shows the inconsistency of
the reported RR among those who had splenectomy ver-
sus those who did no, however, the findings were based
on three studies only. Table 4 also shows the potential
protective role of pelvic RT as reported by De Bruin
et al. [55], where patients receiving that modality showed
a risk that was not as high compared with those who did
not. HL survivors who received RT had a higher risk of
developing estrogen receptor (ER)-negative/progesterone
receptor (PR)-negative SBC as compared with ER-posi-
tive/PR-positive tumors [57].
Discussion
HL has been a successful model for the development of
effective treatment approach in clinical oncology. Long-term survivors of that disease have also allowed better
recognition and understanding of the late effects of ther-
apy. In a large cohort of 25,305 women with HL, and
with 957 incidences of SBC reported from North Ameri-
can and European institutions, the current meta-analysis
quantified the risk of SBC. The overall pooled analysis
showed that there was an approximate 9-fold increase in
the risk of SBC incidence (pooled RR= 8.23), and AER
of 23 patients per 10,000 person-years.
Patients included in this meta-analysis developed HD
at a median age of 23.7 years. There has been incongruity
about the influence of younger age at HL diagnosis and
the higher risk of SBC, where some studies have failed to
prove that effect [39,42]. The current meta-analysis
clearly showed that younger age at HL diagnosis was
associated with increased risk of SBC, and the risk
remained after adjusting for other covariates. Moreover,
we demonstrated that the RR of SBC for women who
developed HL above the age of 40 years was not signifi-
cant. It is presumed that the higher risk associated with
Figure 6 Summary statistics and corresponding forest plot for the relative risk (RR) of second breast cancer based on follow-up
latency since Hodgkin’s lymphoma diagnosis. RRs were calculated using a random-effects model.
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Figure 7 Summary statistics and corresponding forest plot for the relative risk (RR) of second breast cancer vs. treatment modalities.
RRs were calculated using a random-effects model. (R radiotherapy, C chemotherapy, RC combined radiotherapy and chemotherapy).
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RT delivered at a time when breast tissue is proliferating.
RT used as the sole therapeutic modality was asso-
ciated with a 5-fold (RR = 4.70) increase in risk and a 14-fold (RR = 14.08) increase among young (≤ 30 years of
age). Almost all SBC arose within or at the margin of
the RT field. The RR of combined RT and any CT was
slightly higher than that associated with RT only (5.65
Table 4 Relative risk of second breast cancer vs. selected
risk variables
Variable RR (95% CI)
Mediastinal mass +
Wahner-Roedler 2003 [44] 4.22 (2.71, 6.57)
Alm El-Din 2009 [54] 11.46 (6.78, 19.38)
Mediastinal mass -
Wahner-Roedler 2003 [44] 1.70 (0.79, 3.63)
Alm El-Din 2009 [54] 6.09 (2.37, 15.67)
Splenectomy +
Wolden 1998 [30] 2.10 (0.62, 7.16)
Wahner-Roedler 2003 [44] 4.70 (2.87, 7.69)
Alm El-Din 2009 [54] 9.86 (5.42, 17.92)
Splenectomy -
Wahner-Roedler 2003 [44] 1.90 (1.05, 3.45)
Alm El-Din 2009 [54] 9.67 (4.87, 19.20)
Mantle RT, no pelvic RT
De Bruin 2009 [55] 8.20 (6.62, 10.15)
Mediastinal RT, no pelvic RT
De Bruin 2009 [55] 3.71 (1.38, 9.97)
Mantle RT + pelvic RT
De Bruin 2009 [55] 2.70 (1.11, 6.56)
ER-/PR-
Dores 2010 [57] 9.30 (7.00, 12.36)
ER+/PR+
Dores 2010 [57] 4.95 (3.84, 6.39)
CI confidence interval, ER estrogen receptors, PR progesterone receptors, RR
relative risk, RT radiotherapy.
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combination of RT and alkylating CT (RR= 6.59), thus,
the potential protective effect of gonado-toxic alkylating
CT was not demonstrated. Several studies showed an in-
verse association between the use of alkylating CT in HL
and SBC risk [24,65], however, other investigators
reported increased risk [30,66]. In this meta-analysis and
based on data reported from three studies, the risk asso-
ciated with the combination of RT and non-alkylating
CT was not significant [37,54,58], also found insignifi-
cant, was the risk related to the use of CT only.
Analysis of potential additional risk factors was limited
due to lack of sufficient data and/or inability to compute
missing information, therefore, cautions should be
exerted in interpreting results. Two studies [24,54],
reported on the mantle field RT dose where there was
only a small difference in RR between dose< 40 Gy
and ≥ 40 Gy (5.99, and 6.13, respectively). While some
studies showed that subjects with SBC were found to be
significantly more likely to have received higher doses of
mantle RT [52], this observation was complicated by thefact that patients treated with higher radiation doses
have had longer follow-up. Guibout et al. [46], did not
find a significant association between RT dose and SBC,
suggesting that the increased risk after HL may indicate
a specific susceptibility for developing SBC, or a particu-
lar susceptibility to radiation and/or chemotherapy, or
both. Conversely, De Bruin et al. showed that the risk of
SBC is related to the RT volume [55], where mantle field
irradiation was associated with a 2.7-fold increased risk
of SBC compared with mediastinal irradiation alone. Be-
sides, the meta-analysis reported by Franklin et al.
showed a RR of 3 comparing extended field versus
involved field RT [14].
The reason for failing to show a convincing evidence
of RT dose–response effect associated with SBC risk is
at best divisive. There is evidence for a strongly linear
radiation dose response, but only in the lower dose
range (up to 5 or 10 Gy) [67,68]. It has been suggested
that cell killing tends to decrease the carcinogenic effect
of RT along an exponential curve at doses above 10 Gy
[69]. However, it is known that BC is a known complica-
tion of low-dose breast radiation [67], thus BC may re-
main a risk among adolescent women who receive any
dose of thoracic irradiation for HL.
Although new RT techniques and treatment strat-
egies have the potential to reduce the future burden
of late effects, nevertheless, we have shown that an
even higher risk was reported in more recent years sug-
gesting that there remains a significant cohort at an
increased risk of SBC.
Pelvic RT was found to be associated with a protective
effect as reported by De Bruin et al. [55]. The same ef-
fect was also noted by Basu et al., where 3.4% of patients
who developed SBC received pelvic RT as compared
with 26.3% among those who did not [52]. It is pre-
sumed that the protective effect of pelvic RT is attribu-
ted to the induction of premature menopause and the
role played by hormone stimulation in RT-induced
breast carcinogenesis [43,70]. The influence of splenec-
tomy on SBC risk has been controversial. While some
studies reported a modest higher risk [71], other studies
failed to show that effect [30,52].
Only one study examined the receptor status of SBC
[57]. The RR of ER-negative/PR-negative SBC was 66%
higher than ER-positive/PR-positive SBC among 5-year
HL survivors, and nearly two-fold higher among 15-year
survivors. Conversely, other studies of small numbers of
SBC patients have not found a significant variation in
hormone-receptor status when compared with primary
BC controls [72,73]. While the incidence of hormone re-
ceptor-positive BC in the general population exceeds
that of ER-negative/PR-negative BC, it is postulated,
however, that young women treated for HL may experi-
ence premature ovarian failure related to HL therapy,
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from those in the general population.
The present meta-analysis has several limitations.
First, it is not possible to completely exclude the possi-
bility that the HL itself carries with it an increased risk
of second malignancy including SBC. Second, it is very
difficult to quantify the possible effect of confounding
factors such as lifestyle factors, personal risk, family his-
tory, etc. For example, Landgren et al. found increased
RR (1.81) of breast cancer among HL patient with posi-
tive (vs. negative) family history of cancer [50]. Third,
the analyses showed significant heterogeneity in risk es-
timate, nevertheless, investigating heterogeneity using
meta-regression technique showed the dominant role of
age at HL diagnosis. Other limitations include the lack
of comprehensive treatment data including information
on RT dose and additional treatments, and the lack of
sufficient data to model the protective effect of endogen-
ous hormone ablation against the risk associated with
exposure to exogenous hormones. Moreover, it is not
clear if a similar magnitude of risk is to be expected in a
different patient population where the incidence of spor-
adic BC is low. Finally, the meta-analysis lacks the ana-
lysis of SBC outcome. However, SBC incidence rather its
mortality was the main objective of the meta-analysis.
Moreover, not all studies reported on mortality, besides,
analysis of SBC mortality would be confounded by the
mortality from HL itself or its therapy-related effect, as-
certainment of the cause of death, age of diagnosis of
HL or SBC, and length of follow-up.
Conclusions
We conclude that the current meta-analysis provided
the most recent comprehensive estimate of the risk of
SBC in a broad-range of HL survivors with inclusive
analysis of relevant clinical and treatment variables.
Based on the derived data where the median age at the
diagnosis of SBC was 35.0 years and at a median latency
of 17.7 years, screening recommendations for HL survi-
vors need to be reemphasized. The results from the
current meta-analysis support the favorable outcome of
the risk-guided BC screening for such patients according
to three prospective studies [74-76]. It is probably more
appropriate that female patients with HL who are at a
higher risk for developing SBC to be screened annually
and at an earlier age rather than biennially starting at
the age of 50 years as currently recommended for gen-
eral population [77]. Our data also support the recent
trend of risk-adapted management of HL to reduce the
risk of short- and long-term adverse events associated
with needless overtreatment [78].
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